TSXV:BTI.H - Post by User
Comment by
chrispion Dec 18, 2020 6:17pm
205 Views
Post# 32145488
RE:RE:RE:end of year podocast
RE:RE:RE:end of year podocastStockhouse doesn't have an edit button so let me correct that previous post:
one correction prophetoffacts (maybe that shouldn't be your userid ;)
after sitting on 001 for so many years because no one wanted it.
It is not the case that no one wanted xB3-001 ... it was never available for partnering nor sale. We were going to take it to the clinic ourselves as our lead drug. Now, for the various reasons I stated in an earlier post, it makes most sense to partner it.
BTW I'd like to remind readers that Bioasis has two revenue streams: - license xB3 to pharmas to transport their own drugs across the BBB
- use xB3 to get our "own" developed drugs across the BBB and take them to market (of course, partnering at some stage for obvious reasons). And by the way, we are reducing risk in this scenario by combining already proven and prescribed drugs like "Herceptin" with xB3 to form our "own" new, patented drug. In this particular example, xB3-001 is the program name for this particular combination.